VHL gene mutation and hypermethylation in patients with renal cell carcinoma: Preliminary results and clinical correlation

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 9619-9619
Author(s):  
P. E. Shaheen ◽  
S. A. Vaziri ◽  
R. Ganapathi ◽  
P. Elson ◽  
M. Zhou ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Mutation ◽  
Renal Cell ◽  
Clinical Correlation ◽  
Vhl Gene ◽  
Preliminary Results

scholarly journals 216: Low CAIX Expression and Absence of VHL Gene Mutation are Associated with Tumor Aggressiveness and Poor Survival in Patients with Renal Cell Carcinoma (RCC)

2007 ◽  
Vol 177 (4S) ◽  
pp. 72-73
Author(s):  
Jean-Jacques Patard ◽  
Quoc-Dien Trinh ◽  
Pierre I. Karakiewicz ◽  
Patricia Fergelot ◽  
Nathalie Rioux-Leclercq ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Mutation ◽  
Renal Cell ◽  
Tumor Aggressiveness ◽  
Poor Survival ◽  
Vhl Gene ◽  
Caix Expression

Von Hippel-Lindau gene mutation status is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15522-15522
Author(s):  
D. Tsavachidou ◽  
N. M. Tannir ◽  
C. G. Wood ◽  
P. Corn ◽  
K. Do ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Mutation ◽  
Metastatic Disease ◽  
Primary Tumor ◽  
Renal Cell ◽  
Response To Therapy ◽  
Gene Inactivation ◽  
Vhl Gene ◽  
Von Hippel Lindau

15522 Background: A single arm phase II study is underway evaluating the safety and clinical benefit of presurgical bevacizumab and erlotinib in the management of patients with untreated conventional renal cell carcinoma (RCC). It is not known how the presence or absence of von Hippel Lindau (VHL) mutations affect the response to therapy in the primary or metastatic site, and whether VHL mutational status is predictive for either. Methods: Patients enrolled had conventional RCC, measurable metastatic disease, a primary tumor in place, no prior systemic therapy, a PS of 0 or 1 and no brain metastases. A total of 35 patients were enrolled as of January 8, 2007. Patients were treated with bevacizumab for 4 cycles and erlotinib for 8 weeks, and underwent cytoreductive nephrectomy at week 10 (4 weeks after the last dose of bevacizumab). A VHL gene mutation and methylation analysis was completed on nephrectomy specimens from the first 18 evaluable patients. Patients were grouped according to the presence or absence of functional VHL gene inactivation (mutation and/or methylation). Two-sample T-test and Fisher’s exact test were performed. Results: Ten patients (55%) demonstrated either VHL mutation or methylation ( table 1 ). Patients with no VHL gene inactivation demonstrated more robust primary tumor shrinkage, but did not demonstrate partial responses (PRs). Table 1 . Conclusions: These findings, although preliminary, suggest a dichotomous response in the primary and metastatic disease sites according to VHL functional status. Ongoing evaluation of new treatment strategies using antivascular/targeted agents in RCC may benefit from molecular stratification. [Table: see text] No significant financial relationships to disclose.

scholarly journals Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma

2008 ◽  
Vol 123 (2) ◽  
pp. 395-400 ◽  
Author(s):  
Jean-Jacques Patard ◽  
Patricia Fergelot ◽  
Pierre I. Karakiewicz ◽  
Tobias Klatte ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Mutation ◽  
Renal Cell ◽  
Clear Cell ◽  
Tumor Aggressiveness ◽  
Poor Survival ◽  
Cell Renal Cell Carcinoma ◽  
Vhl Gene ◽  
Caix Expression

Role of VHL gene mutation in human renal cell carcinoma

Tumor Biology ◽  
2011 ◽  
Vol 33 (1) ◽  
pp. 9-16 ◽  
Author(s):  
Wani Arjumand ◽  
Sarwat Sultana
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Mutation ◽  
Renal Cell ◽  
Human Renal Cell Carcinoma ◽  
Vhl Gene

780: Carbonic Anhydrase IX (CAIX) Expression and VHL Gene Alteration as Predictors of Survival in Renal Cell Carcinoma

2004 ◽  
Vol 171 (4S) ◽  
pp. 206-207 ◽  
Author(s):  
Hideki Mukouyama ◽  
Masahiro Yao ◽  
David B. Seligson ◽  
John S. Lam ◽  
Yoji Nagashima ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Carbonic Anhydrase ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carbonic Anhydrase Ix ◽  
Vhl Gene ◽  
Gene Alteration ◽  
Caix Expression

scholarly journals VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium

Oncogene ◽  
2001 ◽  
Vol 20 (38) ◽  
pp. 5393-5400 ◽  
Author(s):  
Xin Ma ◽  
Ke Yang ◽  
Per Lindblad ◽  
Lars Egevad ◽  
Kari Hemminki
Keyword(s):  
Renal Cell Carcinoma ◽  
Linkage Disequilibrium ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Founder Mutations ◽  
Vhl Gene ◽  
Gene Alterations

Assessing venous thrombus in renal cell carcinoma: preliminary results for unenhanced 3D-SSFP MRI

2018 ◽  
Vol 73 (8) ◽  
pp. 757.e9-757.e19
Author(s):  
L.C. Adams ◽  
B. Ralla ◽  
G. Engel ◽  
G. Diederichs ◽  
B. Hamm ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Preliminary Results ◽  
Venous Thrombus
Sign in / Sign up

Export Citation Format

Share Document